CARM vs. CTSO, XGN, AWH, LFVN, ADVM, OVID, XBIT, RENB, ZVRA, and GBIO
Should you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Cytosorbents (CTSO), Exagen (XGN), Aspira Women's Health (AWH), LifeVantage (LFVN), Adverum Biotechnologies (ADVM), Ovid Therapeutics (OVID), XBiotech (XBIT), Renovaro (RENB), Zevra Therapeutics (ZVRA), and Generation Bio (GBIO). These companies are all part of the "medical" sector.
Carisma Therapeutics (NASDAQ:CARM) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.
44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 17.0% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 6.6% of Cytosorbents shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Cytosorbents received 424 more outperform votes than Carisma Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Carisma Therapeutics an outperform vote while only 78.99% of users gave Cytosorbents an outperform vote.
Carisma Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.
Cytosorbents has higher revenue and earnings than Carisma Therapeutics. Cytosorbents is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cytosorbents had 1 more articles in the media than Carisma Therapeutics. MarketBeat recorded 1 mentions for Cytosorbents and 0 mentions for Carisma Therapeutics. Carisma Therapeutics' average media sentiment score of 0.98 beat Cytosorbents' score of 0.00 indicating that Carisma Therapeutics is being referred to more favorably in the media.
Cytosorbents has a net margin of -75.07% compared to Carisma Therapeutics' net margin of -538.81%. Cytosorbents' return on equity of -129.89% beat Carisma Therapeutics' return on equity.
Carisma Therapeutics currently has a consensus target price of $9.00, suggesting a potential upside of 733.33%. Cytosorbents has a consensus target price of $2.00, suggesting a potential upside of 125.23%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Cytosorbents.
Summary
Carisma Therapeutics beats Cytosorbents on 10 of the 18 factors compared between the two stocks.
Get Carisma Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Carisma Therapeutics Competitors List
Related Companies and Tools
